Global Deep Brain Stimulation Market Size to Reach USD 4.27 Billion in 2032 | Emergen Research
12 déc. 2023 07h31 HE
|
Emergen Research
Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global Deep Brain Stimulation (DBS) market, valued at USD 1.70 Billion in 2022, is projected to witness a robust revenue Compound Annual Growth Rate...
Deep Brain Stimulation Devices Market to Hit $2,508.5 Million by 2030, Rising at 9.8% CAGR | Coherent Market Insights
10 nov. 2023 08h35 HE
|
CMI
Burlingame, Nov. 10, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global deep brain stimulation device market is estimated to be valued at US$ 1,188.9 million in 2022 and is...
Deep Brain Stimulation (DBS) Devices Market for Parkinson’s Disease to Reach USD 1.2 Bn by 2028 with CAGR of 5.1% - TMR Study
09 mai 2023 06h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, May 09, 2023 (GLOBE NEWSWIRE) -- The global deep brain stimulation devices market for Parkinson’s disease was valued at USD 0.85 Bn in 2020 and is anticipated to...
Oncotelic Announces Formation of Animal Health Division
06 oct. 2022 08h15 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), directly and / or through its wholly owned subsidiaries...
Global Positive Allosteric Modulators Market to Grow at a Significant CAGR During 2022-2031; Market to Grow on the Back of the Increasing Prevalence of Chronic Mental Disorders, Upsurge in the Geriatric Population, and Advancement in R&D
21 juil. 2022 11h21 HE
|
Research Nester
New York, July 21, 2022 (GLOBE NEWSWIRE) -- As per the World Health Organization, anxiety and depressive disorders are estimated to be the most prevalent mental disorders, affecting 1 in 8 persons,...
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
12 mai 2022 08h05 HE
|
Aeterna Zentaris Inc
– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying (“AIM”) Biologicals as a potential...
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
25 avr. 2022 08h05 HE
|
Aeterna Zentaris Inc
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease ("PD"), a neurodegenerative movement disorder ...
Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson’s Disease
29 mars 2022 17h00 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug...
Vyant Bio Issues Letter to Shareholders
01 mars 2022 08h30 HE
|
Vyant Bio, Inc.
Cherry Hill, NJ, March 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological...
Parkinson’s Disease Drugs Market to reach USD 8,383.2 Million by 2026 | Market Projection By Technology, Major key players, Growth, Revenue, CAGR, Regional Analysis, Industry Forecast
15 nov. 2021 04h08 HE
|
Fortune Business Insights
Pune, India, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The Global Parkinson's Disease Drugs Market is likely to grow in the coming years due to the growing emphasis on the treatment of Parkinson's disease....